Arrowstreet Capital
FENC icon

Arrowstreet Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Arrowstreet Capital’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,460
Closed -$250K – 1930
2025
Q4 		$250K Buy
32,460
+5,405
+20% +$44.4K ﹤0.01% 1762
2025
Q3 		$253K Hold
27,055
– – ﹤0.01% 1774
2025
Q2 		$225K Buy
+27,055
New +$185K ﹤0.01% 1866
2024
Q2 		– Sell
-39,909
Closed -$444K – 1597
2024
Q1 		$444K Buy
+39,909
New +$401K ﹤0.01% 1466

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Arrowstreet Capital's FENC Position: Q1 2026 in Review

Arrowstreet Capital sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 32,460 shares — an estimated $250K sold.

Arrowstreet Capital first reported a position in FENC in Q1 2024 and held it in 4 quarters. The position peaked at $444K in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Arrowstreet Capital reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 32,460 Fennec Pharmaceuticals shares in Q1 2026, an estimated $250K.
  • Arrowstreet Capital first reported a position in Fennec Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Arrowstreet Capital's Fennec Pharmaceuticals position peaked at $444K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.